ArticlePharmacology, biochemistry, and behavior2014
Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor 'knockout' mice.
Article in Pharmacology, biochemistry, and behavior, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Norepinephrine regulates hippocampal mitochondrial biogenesis via β2-adrenergic receptor signaling and PGC-1α.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Detrimental effects of atomoxetine on visual signal detection in rats: comparison with ADHD psychomotor stimulant drugs.Psychopharmacology · 2026Article
- Biomarkers for predominantly inattentive ADHD: potential involvement of Wnt/β-catenin/integrin signaling in a spontaneously hypertensive rat.Genes & genomics · 2026Article
- Rodent research of attention-deficit/hyperactivity disorder: insights into widely used animal models.Laboratory animal research · 2025Review
- Adrenoceptors: A Focus on Psychiatric Disorders and Their Treatments.Handbook of experimental pharmacology · 2024Review
- Control of sustained attention and impulsivity by GTranslational psychiatry · 2023Article
- Effect of atomoxetine on ADHD-pain hypersensitization comorbidity in 6-OHDA lesioned mice.Pharmacological reports : PR · 2023Article
- Optogenetic and pharmacological interventions link hypocretin neurons to impulsivity in mice.Communications biology · 2023Article
- Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.Psychopharmacology · 2023Article
- Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats.Biomolecules · 2022Article
- Open-source, Python-based, hardware and software for controlling behavioural neuroscience experiments.eLife · 2022Article
- The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance.Current topics in behavioral neurosciences · 2022Article
- Animal Models of ADHD?Current topics in behavioral neurosciences · 2022Article
- Control of impulsivity by GCommunications biology · 2021Article
- Effect of ADHD medication in male C57BL/6J mice performing the rodent Continuous Performance Test.Psychopharmacology · 2019Article
- Exploring the Validity of Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity Disorder (ADHD).Molecular neurobiology · 2018Review
- Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test.Journal of psychopharmacology (Oxford, England) · 2016Article
- The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorder.Journal of psychopharmacology (Oxford, England) · 2016Article
- Differences in the performance of NK1R-/- ('knockout') and wildtype mice in the 5‑Choice Continuous Performance Test.Behavioural brain research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMice with functional ablation of the neurokinin-1 receptor gene (NK1R(-/-)) display behavioural abnormalities which resemble the hyperactivity, inattention and impulsivity seen in Attention Deficit Hyperactivity Disorder (ADHD). Here, we investigated whether the established ADHD treatment, atomoxetine, alleviates these abnormalities when tested in the light/dark exploration box (LDEB) and 5-Choice Serial Reaction-Time Task (5-CSRTT).
methodsSeparate cohorts of mice were tested in the 5-CSRTT and LDEB after treatment with no injection, vehicle or atomoxetine (5-CSRTT: 0.3, 3 or 10mg/kg; LDEB: 1, 3 or 10mg/kg).
resultsAtomoxetine reduced the hyperactivity displayed by NK1R(-/-) mice in the LDEB at a dose (3mg/kg) which did not affect the locomotor activity of wildtypes. Atomoxetine (10mg/kg) also reduced impulsivity in NK1R(-/-) mice, but not wildtypes, in the 5-CSRTT. No dose of drug affected attention in either genotype.
conclusionsThis evidence that atomoxetine reduces hyperactive/impulsive behaviours in NK1R(-/-) mice consolidates the validity of using NK1R(-/-) mice in research of the aetiology and treatment of ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.